Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis

Archives of Pediatrics and Adolescent Medicine

Volumn 161, Issue 12, 2007, Pages 1176-1182

  Mikaeloff, Yann ^a   Caridade, Guillaume ^a   Rossier, Mélanie ^a   Suissa, Samy ^b   Tardieu, Marc ^a  

^a BICÊTRE HOSPITAL   (France)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CASE CONTROL STUDY; CHILDHOOD; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PRIORITY JOURNAL; RISK; SCHOOL CHILD; VACCINATION;

ADOLESCENT; AGE FACTORS; CASE-CONTROL STUDIES; CHILD; CHILD WELFARE; FEMALE; FRANCE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; MALE; MULTIPLE SCLEROSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 36849023932     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpedi.161.12.1176     Document Type: Article

References (28)

1. Sturkenboom M, Abenhaim L, Wolfson C, Roullet E, Heinzlef O, Gout O. Vaccinations, demyelination and multiple sclerosis study (VDAMS): a population-based study in the UK. Pharmacoepidemiol Drug Saf. 1999;8(suppl 2):S170-S171.
2. Zipp F, Weil JG, Einhaupl KM. No increase in demyelinating diseases after hepatitis B vaccination. Nat Med. 1999;5(9):964-965.
3. Sadovnick AD, Scheifele DW. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet. 2000;355(9203):549- 550.
4. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001;344(5):327-332.
5. Touzé E, Gout O, Verdier-Taillefer MH, Lyon-Caen O, Alpérovitch A. The first episode of central nervous system demyelinization and hepatitis B vaccination [in French]. Rev Neurol (Paris). 2000;156(3):242-246.
6. Touzé E, Fourrier A, Rue-Fenouche C, et al. Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology. 2002;21(4):180-186.
7. DeStefano F, Verstraeten T, Jackson LA, et al; Vaccine Safety Datalink Research Group, National Immunization Program, Centers for Disease Control and Prevention. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60(4):504-509.
8. DeStefano F, Weintraub ES, Chen RT. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology. 2005;64(7):1317.
9. Hernán MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology. 2004;63(5):838-842.
10. Hernán MA, Jick SS. Hepatitis B vaccination and multiple sclerosis: the jury is still out. Pharmacoepidemiol Drug Saf. 2006;15(9):653-655.
11. Kane M, Clements J, Hu D. Hepatitis B. In: Jamison DT, Mosley WH, Measham AR, Bobadilla JL, eds. Disease Control Priorities in Developing Countries. New York, NY: Oxford University Press; 1993:321-330.
12. Denis F. Hepatitis B vaccination in France: vaccination coverage in 2002. Bull Acad Natl Med. 2004;188(1):115-123.
13. Mikaeloff Y, Suissa S, Vallee L, et al; KIDMUS Study Group. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr. 2004;144(2):246-252.
14. Mikaeloff Y, Adamsbaum C, Husson B, et al; KIDMUS Study Group on Radiation. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain. 2004;127(pt 9):1942-1947.
15. Mikaeloff Y, Caridade G, Assi S, Suissa S, Tardieu M. Prognostic factors and early severity score in a cohort of childhood multiple sclerosis. Pediatrics. 2006;118(3):1133-1139.
16. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50(1):121-127.
17. National Institute for Statistics and Economic Studies. Nomenclature des professions et catégories professionnelles 2003. Paris, France: National Institute for Statistics and Economic Studies; 2003.
18. Naismith RT, Cross AH. Does the hepatitis B vaccine cause multiple sclerosis? Neurology. 2004;63(5):772-773.
19. Rodrigues LC, Smith PG. Use of the case-control approach in vaccine evaluation: efficacy and adverse effects. Epidemiol Rev. 1999;21(1):56-72.
20. Grimes DA, Schulz KF. Compared to what? finding controls for case-control studies. Lancet. 2005;365(9468):1429-1433.
21. Bernstein L. Control recruitment in population-based case-control studies. Epidemiology. 2006;17(3):255-257.
22. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343(25):1826-1832.
23. Chen RT. Special methodological issues in pharmacoepidemiology studies of vaccine safety. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. New York, NY: John Wiley & Sons Inc; 2000:707-732.
24. Fine PE, Chen RT. Confounding in studies of adverse reactions to vaccine. Am J Epidemiol. 1992;136(2):121-135.
25. Alizadeh M, Genin E, Babron MC, et al; French Multiple Sclerosis Genetics Group. Genetic analysis of multiple sclerosis in Europeans: French data. J Neuroimmunol. 2003;143(1-2):74-78.
26. Piaggio E, Ben Younes A, Desbois S, et al. Hepatitis B vaccination and central nervous system demyelination: an immunological approach. J Autoimmun. 2005;24(1):33-37.
27. Schattner A. Consequence or coincidence? the occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005;23(30):3876-3886.
28. Mikaeloff Y, Caridade G, Assi S, Tardieu M, Suissa S; KIDSEP Study Group of the French Neuropaediatric Society. Hepatitis B vaccine and risk of relapse after first childhood CNS inflammatory demyelination. Brain. 2007;130(pt 4):1105-1110.